-
Posted by
Two Blokes Apr 22 -
Filed in
Stock
-
6 views
The Health Care sector outperformed the S&P 500 in 2025, with XLV returning -1.5% YTD compared to SPY's -10% decline. Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations, but concerns over Gardasil and Keytruda's patent expirations have weighed on the stock.
